ABVC BioPharma, Inc. Net Income (Loss) Allocated to General Partners
ABVC BioPharma, Inc. (ABVC) reported Net Income (Loss) Allocated to General Partners of $5.25 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:NetIncomeLossAllocatedToGeneralPartners · last filed 2024-08-14
- 2024-06-30: Net Income (Loss) Allocated to General Partners 6 month $5.25M.
| Period end | Net Income (Loss) Allocated to General Partners 6 month |
|---|---|
| 2024-06-30 | $5.25M 10-Q · filed 2024-08-14 |